Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program

BACKGROUND. In the phase III ALSYMPCA trial, metastatic castration‐resistant prostate cancer (mCRPC) patients had few prior life‐prolonging therapies. Following ALSYMPCA, which demonstrated radium‐223 survival benefit, and before radium‐223 U.S. commercial availability, an expanded access program (E...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncologist
Κύριοι συγγραφείς: Sartor, Oliver, Vogelzang, Nicholas J., Sweeney, Christopher, Fernandez, Daniel C., Almeida, Fabio, Iagaru, Andrei, Brown, Alan, Smith, Matthew R., Agrawal, Manish, Dicker, Adam P., Garcia, Jorge A., Lutzky, Jose, Wong, Yu‐Ning, Petrenciuc, Oana, Gratt, Jeremy, Shore, Neal D., Morris, Michael J.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: AlphaMed Press 2017
Θέματα:
Genitourinary Cancer
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813754/
https://ncbi.nlm.nih.gov/pubmed/29183960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0413
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια